0.0000 (0.0000%)
  • Bid / Lots
    9.0000/ 10
  • Ask / Lots
    0.0000/ 0
  • Open / Previous Close
    0.0000 / 13.1700
  • Day Range
  • 52 Week Range
    Low 7.9000
    High 20.9500
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 13.32
09:32 ET18913.33
10:10 ET10012.89
10:19 ET10012.8501
10:26 ET10012.74
10:28 ET11012.87
11:13 ET37012.92
12:30 ET20012.82
12:32 ET10012.78
12:34 ET20012.69
12:59 ET10012.89
01:24 ET20012.71
01:51 ET10012.92
01:53 ET10012.9
02:42 ET28412.805
02:45 ET10012.9
02:49 ET10012.77
03:09 ET10012.94
03:12 ET20012.95
03:14 ET20013.07
03:20 ET40013.29
03:21 ET10013.4
03:23 ET77813.06
03:27 ET20013.25
03:32 ET100013.55
03:34 ET10013.57
03:38 ET10013.7
03:39 ET10013.66
03:41 ET10013.62
03:43 ET10013.58
03:45 ET10013.57
03:50 ET70013.41
03:56 ET70613.21
03:57 ET60013.12
03:59 ET70013.17
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesHLVX
Hillevax Inc
United StatesPRE
Prenetics Global Ltd
United StatesALDX
Aldeyra Therapeutics Inc
United StatesGBIO
Generation Bio Co
United StatesTYRA
Tyra Biosciences Inc
United StatesBTAI
BioXcel Therapeutics Inc
As of 2022-08-10

Company Information

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-214 comprises VLPs for the two major genotypes of norovirus: GI.1 and GII.4. The Company's clinical development plan is focused on infants.

Contact Information

75 State St., Suite 100BOSTON, MA, United States 02109


Chairman of the Board, President, Chief Executive Officer
Robert Hershberg
Chief Financial Officer, Chief Business Officer
David Socks
Chief Operating Officer, Director
Aditya Kohli
Senior Vice President - Regulatory Affairs
Kaia Agarwal
Chief Administrative Officer, General Counsel, Company Secretary
Paul Bavier

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.